Thursday, May 10, 2012

Tofacitinib

  • (CBS/AP) A new rheumatoid arthritis drug considered to be the first of its kind got backed by a Food and Drug Administration (FDA) advisory panel Wednesday, putting the drug a step closer to hitting the market.
  • (CBS News)
  • SILVER SPRING, Md., May 9 (Reuters) - Pfizer Inc won support from a U.S. advisory panel on Wednesday for its arthritis drug, which the worlds top drugmaker hopes will give it a major boost after a wave of patent expiries.
  • (Huffington Post)
  • Pfizer Inc. (NYSE:PFE) announced today that the Arthritis Advisory Committee to the U.S.
  • (PharmiWeb)
  • SILVER SPRING, Md. -- An FDA advisory committee has voted 8-2 in favor of recommending approval of the oral JAK inhibitor tofacitinib for the treatment of rheumatoid arthritis.
  • (MedPage Today)
  • This article is provided to FT.com readers by BioPharm Insight—a news service focused on providing insight into the most price sensitive issues in the global pharmaceutical market. www.biopharminsight.
  • (Financial Times)
  • SILVER SPRING, MD. – There soon may be a new oral disease-modifying antirheumatic drug in town, the first in more than 10 years to be approved for the treatment of rheumatoid arthritis.
  • (familypracticenews.com)
  • May 9, 2012 — The US Food and Drug Administration Arthritis Advisory Committee voted 8-2 today to recommend the approval of tofacitinib, the first oral drug to treat rheumatoid arthritis.
  • (Medscape News)
  • A federal advisory panel recommended approval of a rheumatoid arthritis pill known as tofacitinib, but several members expressed concern about its safety.
  • (New York Times)
  • Tofacitinib, taken orally, could serve as an alternative approach to treating moderate to severe patients who did not respond to one or more traditional therapies, said the advisory committee.
  • (medicalxpress.com)

No comments:

Post a Comment